Pharmaust Ltd
ASX:PAA

Watchlist Manager
Pharmaust Ltd Logo
Pharmaust Ltd
ASX:PAA
Watchlist
Price: 0.165 AUD -8.33% Market Closed
Market Cap: AU$81.2m

Net Margin

-885.9%
Current
Declining
by 406.4%
vs 3-y average of -479.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-885.9%
=
Net Income
AU$-7.7m
/
Revenue
AU$866.2k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-885.9%
=
Net Income
AU$-7.7m
/
Revenue
AU$866.2k

Peer Comparison

Country Company Market Cap Net
Margin
AU
Pharmaust Ltd
ASX:PAA
81.2m AUD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
440.4B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Lower than 73% of companies in Australia
Percentile
27th
Based on 4 004 companies
27th percentile
-885.9%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Pharmaust Ltd
Glance View

Market Cap
81.2m AUD
Industry
Pharmaceuticals

PharmAust Ltd. is a pharmaceutical company, which provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2001-10-05. The firm is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for pet dogs. The firm's lead candidate, monepantel (MPL), is a small molecule drug primarily being developed as a safe and potent treatment for cancer. The MPL can also be used for neurodegenerative diseases such as Motor Neuron Disease, Parkinson's Disease, and Alzheimer's Disease. The company has completed Phase I clinical trials with MPL in humans and dogs diagnosed with solid tumors. The firm has also initiated a preclinical program to screen its portfolio of aminoacetonitrile (AAD) compounds for anticancer activity.

PAA Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-885.9%
=
Net Income
AU$-7.7m
/
Revenue
AU$866.2k
What is Pharmaust Ltd's current Net Margin?

The current Net Margin for Pharmaust Ltd is -885.9%, which is below its 3-year median of -479.5%.

How has Net Margin changed over time?

Over the last 3 years, Pharmaust Ltd’s Net Margin has decreased from -36.4% to -885.9%. During this period, it reached a low of -885.9% on Jul 30, 2024 and a high of -13.4% on Dec 31, 2022.

Back to Top